Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
---|
03/26/2009 | US20090081652 Constitutively Translocating Cell Line |
03/26/2009 | US20090081651 METHODS FOR ISOLATING AND CHARACTERIZING ENDOGENOUS mRNA-PROTEIN (mRNP) COMPLEXES |
03/26/2009 | US20090081645 Method of assuming drug sensitivity to cdk4 inhibitor |
03/26/2009 | US20090081642 Novel apoptosis gene EI24, compositions, and methods of use |
03/26/2009 | US20090081637 Screening nucleic acid comprising sequence that encodes reverse transciptase domain of DNA polymerase for adefovir-resistant mutations; use in vaccine development |
03/26/2009 | US20090081635 Modified heparinase iii and methods of sequencing therewith |
03/26/2009 | US20090081354 Phytate Polynucleotides and Methods of Use |
03/26/2009 | US20090081353 Corn plants and seed enhanced for asparagine and protein |
03/26/2009 | US20090081331 Phytase |
03/26/2009 | US20090081283 Tumor therapy with non-viral-based high affinitiy laminin receptor-targeted vectors |
03/26/2009 | US20090081280 Compositions and methods for modulating hemostasis |
03/26/2009 | US20090081263 Double-stranded rna oligonucleotides which inhibit tyrosinase expression |
03/26/2009 | US20090081256 Transgenic plant-based vaccines |
03/26/2009 | US20090081251 Production of Viral Vaccines in Suspension on Avian Embryonic Derived Stem Cell Lines |
03/26/2009 | US20090081248 Non-hemolytic LLO fusion proteins and methods of utilizing same |
03/26/2009 | US20090081243 Agents and methods for diagnosing stress |
03/26/2009 | US20090081242 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
03/26/2009 | US20090081241 comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein |
03/26/2009 | US20090081240 Human Anti-Kir Antibodies |
03/26/2009 | US20090081239 bind and neutralize Plasminogen Activator Inhibitor-1 (PAI-1) by converting PAI-1 to its latent form or increasing proteolytic cleavage; treating a fibrotic condition; inhibits accumulation of extracellular matrix (ECM) |
03/26/2009 | US20090081238 Anti-notch1 NRR antibodies and methods using same |
03/26/2009 | US20090081230 Human cytomegalovirus neutralising antibodies and use thereof |
03/26/2009 | US20090081229 Anti-pro87299 antibodies |
03/26/2009 | US20090081228 Cyr61 compositions and methods |
03/26/2009 | US20090081227 Promotong differentiation of neural stem cells to nerve cells for use in treating injury to central nerve system caused by brain infarction, hemorrhage and/or spinal cord injury |
03/26/2009 | US20090081225 PIF peptides biologic activities, site of action, and the antibody to detect PIF |
03/26/2009 | US20090081224 Compositions of polypeptides specific to pathogenic strains and their use as vaccines and in immunotheraphy |
03/26/2009 | US20090081222 Novel splice variants of the egf receptor |
03/26/2009 | US20090081215 Genetic products differentially expressed in tumors and use thereof |
03/26/2009 | US20090081214 Genetic products differentially expressed in tumors and use thereof |
03/26/2009 | US20090081210 Methods of Killing Tumor Cells by Targeting Internal Antigens Exposed on Apoptotic Tumor Cells |
03/26/2009 | US20090081209 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins |
03/26/2009 | US20090081207 High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity |
03/26/2009 | US20090081202 Immunogenic compositions and methods |
03/26/2009 | US20090081193 Hemagglutinin polypeptides, and reagents and methods relating thereto |
03/26/2009 | US20090081185 Apoptotic agents |
03/26/2009 | US20090081178 Phenolic Binding Peptides |
03/26/2009 | US20090081172 Nucleic acid encoding a receptor other than an immunoglobulin, wherein the receptor binds to a MUC 1 tumor antigen independently of a major histocompatibility complex (MHC); activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor |
03/26/2009 | US20090081166 Colonization factor (CF) antigens of enterotoxigenic escherichia coli in recombinant bacteria |
03/26/2009 | US20090081144 Cosmetic compositions |
03/26/2009 | US20090081131 Tumor therapy with high affinity laminin receptor-targeted vectors and compounds |
03/26/2009 | US20090081127 Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response |
03/26/2009 | US20090081126 Novel fully human anti-VAP-1 monoclonal antibodies |
03/26/2009 | US20090081125 Angiogenetic Agent Containing Adrenomedulin as the Active Ingredient |
03/26/2009 | US20090081124 Virus coat protein/receptor chimeras and methods of use |
03/26/2009 | US20090081119 Inhibiting dna polymerase beta to enhance efficacy of anticancer agents |
03/26/2009 | US20090078645 Plant Capable of Accumulating Inorganic Phosphate at High Level and Use of the Plant |
03/26/2009 | US20090078574 Charge tags and the separation of nucleic acid molecules |
03/26/2009 | US20090078384 Esterases from rumen |
03/26/2009 | CA2712326A1 Plants with increased yield |
03/26/2009 | CA2711818A1 Method of reducing the effects of cytostatic drugs on bone marrow derived cells, and methods of screening |
03/26/2009 | CA2706889A1 Mutant pyrrolysyl-trna synthetase, and method for production of protein having non-natural amino acid integrated therein by using the same |
03/26/2009 | CA2701871A1 Plants with increased yield |
03/26/2009 | CA2700476A1 Methods and compositions for detection of ehrlichia chaffeensis (vlpt) |
03/26/2009 | CA2700474A1 Methods and compositions for detection of ehrlichia chaffeensis (p120) |
03/26/2009 | CA2700294A1 Plants having increased yield-related traits and a method for making the same |
03/26/2009 | CA2700265A1 Compositions and methods for altering the morphology of plants |
03/26/2009 | CA2700115A1 Long interspersed nuclear element polypeptide compositions and methods of use thereof |
03/26/2009 | CA2700047A1 Hypoallergenic variants of the major allergen from betula verrucosa pollen |
03/26/2009 | CA2699998A1 Compositions comprising stat5 sirna and methods of use thereof |
03/26/2009 | CA2699995A1 Compositions comprising stat3 sirna and methods of use thereof |
03/26/2009 | CA2699958A1 Identification and isolation of fetal cells and nucleic acid |
03/26/2009 | CA2699944A1 Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
03/26/2009 | CA2699638A1 Down-regulation of the gene expression by means of nucleic acid-loaded virus-like particles |
03/26/2009 | CA2698908A1 Methods of refining hydrocarbon feedstocks |
03/26/2009 | CA2698667A1 Human gm-csf antigen binding proteins |
03/26/2009 | CA2698460A1 Compositions and methods for the modification of physiological responses in plants |
03/26/2009 | CA2698130A1 Modified xylan production |
03/26/2009 | CA2694494A1 Hpiv-2 variants and medical applications thereof |
03/25/2009 | EP2040187A1 Gene information processing apparatus and gene information display apparatus |
03/25/2009 | EP2039782A2 Method and apparatus for judging the presence or absence of cancer cell |
03/25/2009 | EP2039779A1 Screening method |
03/25/2009 | EP2039774A1 Methods for the production of products in host cells |
03/25/2009 | EP2039773A1 Mutant vesicular stomatitis viruses and use thereof |
03/25/2009 | EP2039772A2 Method for improved utilization of the production potential of transgenic plants introduction |
03/25/2009 | EP2039771A2 Method for improved utilization of the production potential of transgenic plants |
03/25/2009 | EP2039770A2 Method for improved utilization of the production potential of transgenic plants |
03/25/2009 | EP2039769A2 Antimicrobial peptides and methods of use |
03/25/2009 | EP2039768A1 Mutant forms of Fas ligand and uses thereof |
03/25/2009 | EP2039767A1 PNA conjugates targeted to the EMU enhancer of the IGH locus as therapeutic agent for BCL-2 translocation-driven follicular cell lymphoma clonal expansion |
03/25/2009 | EP2039766A1 Immunocompetent cell having anti-cd38 antibody on its cell surface |
03/25/2009 | EP2039765A1 Method for determination of 1,5-anhydroglucitol, and reagent composition for determination of 1,5-anhydroglucitol |
03/25/2009 | EP2039764A1 Truncated secretory aspartyl proteinase 2 |
03/25/2009 | EP2039762A2 Nitralases |
03/25/2009 | EP2039704A1 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
03/25/2009 | EP2039367A1 Prophylactic/therapeutic agent for neurodegenerative disease |
03/25/2009 | EP2039251A1 Methods for generating genetically altered antibody-producing cell lines with improved antibody characteristics |
03/25/2009 | EP2039239A1 Method for preventing mutation of pathogens exposed to transgenic plants |
03/25/2009 | EP2038421A2 A molecular tool to enhance salt tolerance in an organism |
03/25/2009 | EP2038420A2 Use of multiple transformation enhancer sequences to improve plant transformation efficiency |
03/25/2009 | EP2038419A1 Transplastomic plants expressing lumen-targeted protein |
03/25/2009 | EP2038418A2 Dna molecules and methods |
03/25/2009 | EP2038417A2 Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
03/25/2009 | EP2038416A1 Nitrogen limitation adaptibility gene and protein and modulation thereof |
03/25/2009 | EP2038415A1 Dph2 gene deletion mutant and uses thereof |
03/25/2009 | EP2038414A2 Cancer therapy using bcl-xl-specific sina |
03/25/2009 | EP2038413A2 Apparatus, compositions, and methods for assessment of chronic obstructive pulmonary disease progression among rapid and slow decline conditions |
03/25/2009 | EP2038412A1 Polynucleotides encoding caryophyllene synthase and uses thereof |
03/25/2009 | EP2038409A2 Novel human acidic mammalian chitinase and use thereof |
03/25/2009 | EP2038408A1 Preparation of dough and baked products |